Enterovirus D68 serosurvey: evidence for endemic circulation in the Netherlands, 2006 to 2016.
Adolescent
Adult
Age Distribution
Aged
Antibodies, Neutralizing
/ analysis
Antibodies, Viral
/ blood
Child
Child, Preschool
Disease Outbreaks
Enterovirus D, Human
/ genetics
Enterovirus Infections
/ blood
Humans
Infant
Middle Aged
Netherlands
/ epidemiology
Neutralization Tests
Prevalence
Seroepidemiologic Studies
AFM
EV-D68
acute flaccid myelitis
enterovirus D-68
non-polio enteroviruses
outbreak
picornavirus
surveillance
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
25
7
2020
Statut:
ppublish
Résumé
BackgroundEnterovirus D68 (EV-D68) has caused major outbreaks of severe respiratory illness worldwide since 2010.AimOur aim was to evaluate EV-D68 circulation in the Netherlands by conducting a serosurvey of EV-D68 neutralising antibodies (nAb) among the Dutch general population.MethodsWe screened 280 sera from children and adults in the Netherlands and used two independent sets of samples collected in the years 2006 and 2007 and in the years 2015 and 2016, time points before and after the first EV-D68 upsurge in 2010. Neutralisation capacity of the sera was tested against the prototype Fermon EV-D68 strain isolated in 1962 and against a recent EV-D68 strain (genotype B3) isolated in France in 2016.ResultsRegardless of the time of serum collection, we found remarkably high overall seropositivity (94.3-98.3%) for nAb against both EV-D68 strains. Geometric mean titres increased in an age-dependent manner.ConclusionsOur data suggest that EV-D68 has been circulating in the Netherlands for decades and that the enterovirus surveillance does not accurately capture the prevalence of this clinically relevant pathogen.
Identifiants
pubmed: 31481149
doi: 10.2807/1560-7917.ES.2019.24.35.1800671
pmc: PMC6724466
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Gen Virol. 2004 Sep;85(Pt 9):2577-84
pubmed: 15302951
Neth J Med. 2009 Jul-Aug;67(7):301-8
pubmed: 19687529
J Med Virol. 2010 Nov;82(11):1940-9
pubmed: 20872722
J Clin Virol. 2011 Oct;52(2):103-6
pubmed: 21802981
Virology. 2012 Feb 5;423(1):49-57
pubmed: 22177700
J Gen Virol. 2012 Sep;93(Pt 9):1952-8
pubmed: 22694903
J Virol. 2014 Mar;88(5):2374-84
pubmed: 24371050
MMWR Morb Mortal Wkly Rep. 2014 Sep 12;63(36):798-9
pubmed: 25211545
Euro Surveill. 2014 Oct 23;19(42):null
pubmed: 25358039
J Clin Virol. 2015 Jan;62:1-5
pubmed: 25542461
Euro Surveill. 2015 Mar 12;20(10):21062
pubmed: 25788251
PLoS One. 2015 Mar 23;10(3):e0118529
pubmed: 25799541
J Clin Virol. 2015 Aug;69:172-5
pubmed: 26209401
Lancet Infect Dis. 2016 May;16(5):e64-e75
pubmed: 26929196
Clin Infect Dis. 2016 Sep 15;63(6):737-745
pubmed: 27318332
Microbiol Spectr. 2016 Jun;4(3):
pubmed: 27337448
Emerg Infect Dis. 2016 Aug;22(8):1387-94
pubmed: 27434186
Emerg Infect Dis. 2017 Jan;23(1):140-143
pubmed: 27660916
Euro Surveill. 2016 Sep 29;21(39):
pubmed: 27719752
Emerg Microbes Infect. 2017 May 10;6(5):e32
pubmed: 28487560
Pediatr Infect Dis J. 2017 Dec;36(12):1214-1216
pubmed: 28661963
Sci Rep. 2017 Sep 21;7(1):12075
pubmed: 28935894
Euro Surveill. 2017 Nov;22(45):null
pubmed: 29162204
Euro Surveill. 2018 Jan;23(3):
pubmed: 29386095
J Clin Virol. 2018 Apr;101:11-17
pubmed: 29414181
Science. 2018 Aug 24;361(6404):800-803
pubmed: 30139872